|   From the Trenches

Immuno-Oncology: The Comeback Kid

Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   Press Release

Atlas Venture Welcomes Jodie Morrison as Venture Partner

Atlas Venture, a leading early stage venture capital firm, announced today that Jodie Morrison is joining the firm as a venture partner. Jodie will work with the Atlas team to build transformative new biotech companies.

Read more.


  |   From the Trenches

SPAC downpour continues

Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity.

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Playing To Win: Building A Position Of Strength In Biotech

When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not enough to just conquer Australia. If you want to use the continent as a launch pad to take over the world, you need to design and execute on a long-term strategy.

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Targeted Protein Degradation: The First Proof-of-Mechanism in a Randomized, Placebo-Controlled Study

The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis – the promise of these advantages has made targeted protein degradation one of the most exciting new therapeutic modalities of the past 30 years.

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.